These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32307089)

  • 1. Clinical, Demographic, and Imaging Correlates of Anemia in Heart Failure With Preserved Ejection Fraction (from the RELAX Trial).
    Parcha V; Patel N; Kalra R; Bhargava A; Prabhu SD; Arora G; Arora P
    Am J Cardiol; 2020 Jun; 125(12):1870-1878. PubMed ID: 32307089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study.
    Lindman BR; Dávila-Román VG; Mann DL; McNulty S; Semigran MJ; Lewis GD; de las Fuentes L; Joseph SM; Vader J; Hernandez AF; Redfield MM
    J Am Coll Cardiol; 2014 Aug; 64(6):541-9. PubMed ID: 25104521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure).
    AbouEzzeddine OF; Haines P; Stevens S; Nativi-Nicolau J; Felker GM; Borlaug BA; Chen HH; Tracy RP; Braunwald E; Redfield MM
    JACC Heart Fail; 2015 Mar; 3(3):245-52. PubMed ID: 25742762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study.
    Zakeri R; Borlaug BA; McNulty SE; Mohammed SF; Lewis GD; Semigran MJ; Deswal A; LeWinter M; Hernandez AF; Braunwald E; Redfield MM
    Circ Heart Fail; 2014 Jan; 7(1):123-30. PubMed ID: 24162898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the Obese Phenotype of Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study.
    Reddy YNV; Lewis GD; Shah SJ; Obokata M; Abou-Ezzedine OF; Fudim M; Sun JL; Chakraborty H; McNulty S; LeWinter MM; Mann DL; Stevenson LW; Redfield MM; Borlaug BA
    Mayo Clin Proc; 2019 Jul; 94(7):1199-1209. PubMed ID: 31272568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) Trial.
    Hussain I; Mohammed SF; Forfia PR; Lewis GD; Borlaug BA; Gallup DS; Redfield MM
    Circ Heart Fail; 2016 Apr; 9(4):e002729. PubMed ID: 27072860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin D deficiency in patients with diastolic dysfunction or heart failure with preserved ejection fraction.
    Nolte K; Herrmann-Lingen C; Platschek L; Holzendorf V; Pilz S; Tomaschitz A; Düngen HD; Angermann CE; Hasenfuß G; Pieske B; Wachter R; Edelmann F
    ESC Heart Fail; 2019 Apr; 6(2):262-270. PubMed ID: 30784226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-6 in Patients With Heart Failure and Preserved Ejection Fraction.
    Alogna A; Koepp KE; Sabbah M; Espindola Netto JM; Jensen MD; Kirkland JL; Lam CSP; Obokata M; Petrie MC; Ridker PM; Sorimachi H; Tchkonia T; Voors A; Redfield MM; Borlaug BA
    JACC Heart Fail; 2023 Nov; 11(11):1549-1561. PubMed ID: 37565977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-Like Growth Factor-Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction: Results From the RELAX Trial.
    Gandhi PU; Gaggin HK; Redfield MM; Chen HH; Stevens SR; Anstrom KJ; Semigran MJ; Liu P; Januzzi JL
    JACC Heart Fail; 2016 Nov; 4(11):860-869. PubMed ID: 27744089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity.
    Reddy YNV; Rikhi A; Obokata M; Shah SJ; Lewis GD; AbouEzzedine OF; Dunlay S; McNulty S; Chakraborty H; Stevenson LW; Redfield MM; Borlaug BA
    Eur J Heart Fail; 2020 Jun; 22(6):1009-1018. PubMed ID: 32150314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction.
    AbouEzzeddine OF; McKie PM; Dunlay SM; Stevens SR; Felker GM; Borlaug BA; Chen HH; Tracy RP; Braunwald E; Redfield MM
    J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28214792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial.
    Borlaug BA; Anstrom KJ; Lewis GD; Shah SJ; Levine JA; Koepp GA; Givertz MM; Felker GM; LeWinter MM; Mann DL; Margulies KB; Smith AL; Tang WHW; Whellan DJ; Chen HH; Davila-Roman VG; McNulty S; Desvigne-Nickens P; Hernandez AF; Braunwald E; Redfield MM;
    JAMA; 2018 Nov; 320(17):1764-1773. PubMed ID: 30398602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sildenafil Treatment in Heart Failure With Preserved Ejection Fraction: Targeted Metabolomic Profiling in the RELAX Trial.
    Wang H; Anstrom K; Ilkayeva O; Muehlbauer MJ; Bain JR; McNulty S; Newgard CB; Kraus WE; Hernandez A; Felker GM; Redfield M; Shah SH
    JAMA Cardiol; 2017 Aug; 2(8):896-901. PubMed ID: 28492915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Beta-Blocker Use With Exercise Capacity in Participants With Heart Failure With Preserved Ejection Fraction: A Post Hoc Analysis of the RELAX Trial.
    Patel L; Segar MW; Keshvani N; Subramanian V; Pandey A; Chandra A
    Am J Cardiol; 2024 Apr; 216():48-53. PubMed ID: 38336082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contributions of anemia to exercise intolerance in heart failure with preserved ejection fraction-An exercise stress echocardiographic study.
    Naito A; Obokata M; Kagami K; Harada T; Sorimachi H; Yuasa N; Saito Y; Kato T; Wada N; Adachi T; Ishii H
    Int J Cardiol Heart Vasc; 2023 Oct; 48():101255. PubMed ID: 37794956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal Dysfunction in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial.
    Patel RB; Mehta R; Redfield MM; Borlaug BA; Hernandez AF; Shah SJ; Dubin RF
    J Card Fail; 2020 Mar; 26(3):233-242. PubMed ID: 31931098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.
    Kosmala W; Holland DJ; Rojek A; Wright L; Przewlocka-Kosmala M; Marwick TH
    J Am Coll Cardiol; 2013 Oct; 62(15):1330-8. PubMed ID: 23916925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic Gain Index and Exercise Capacity in Heart Failure With Preserved Ejection Fraction.
    Morales-Oyarvide V; Richards D; Hendren NS; Michelis K; Chaikijurajai T; MacNamara JP; Sarma S; Farr MA; Drazner MH; Tang WHW; Grodin JL
    Am J Cardiol; 2023 Mar; 190():17-24. PubMed ID: 36543076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial.
    DeVore AD; McNulty S; Alenezi F; Ersboll M; Vader JM; Oh JK; Lin G; Redfield MM; Lewis G; Semigran MJ; Anstrom KJ; Hernandez AF; Velazquez EJ
    Eur J Heart Fail; 2017 Jul; 19(7):893-900. PubMed ID: 28194841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pro-Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction.
    Abernethy A; Raza S; Sun JL; Anstrom KJ; Tracy R; Steiner J; VanBuren P; LeWinter MM
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29650706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.